Adverum Biotechnologies
Stock Forecast, Prediction & Price Target
Adverum Biotechnologies (ADVM) stock Price Target by analysts
$19
Potential upside: 569.01%
Adverum Biotechnologies price prediction
What is Adverum Biotechnologies stock analysts` prediction?
Adverum Biotechnologies stock forecast: Based on 2 Wall Street analysts` predicted price targets for Adverum Biotechnologies in the last 3 months, the avarage price target is $19, with a high forecast of $NaN. The average price target represents a 569.01% change from the last price of $2.84.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Adverum Biotechnologies stock Price Target by analysts
Full breakdown of analysts given Adverum Biotechnologies price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Luca Issi RBC Capital | 0% 0/2 | 11 months ago | $10 252.11% upside | $7.72 | StreetInsider | Previous targets (1) |
Francois Brisebois Oppenheimer | 0% 0/1 | 12 months ago | $28 885.91% upside | $7.81 | StreetInsider | Previous targets (0) |
Graig Suvannavejh Mizuho Securities | 0% 0/1 | about 1 year ago | $20 604.22% upside | $7.5 | StreetInsider | Previous targets (0) |
Luca Issi RBC Capital | 0% 0/2 | about 1 year ago | $12 322.53% upside | $6.64 | TheFly | Previous targets (1) |
Unknown Chardan Capital | N/A | almost 3 years ago | $2 -29.57% downside | $0.71 | Benzinga | N/A |
Adverum Biotechnologies Financial Estimates
Adverum Biotechnologies Revenue Estimates
Adverum Biotechnologies EBITDA Estimates
Adverum Biotechnologies Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $7.5M N/A | $0 -100% | $3.6M 0% | Avg: $7.69M Low: $7.69M High: $7.69M avg. 113.84% | Avg: $12.30M Low: $12.30M High: $12.30M avg. 59.79% | Avg: $20.10M Low: $20.10M High: $20.10M avg. 63.46% | Avg: $37.75M Low: $37.75M High: $37.75M avg. 87.73% |
Net Income
% change YoY
| $-145.54M N/A | $-154.53M -6.18% | $-117.16M 24.18% | Avg: $-141.73M Low: $-84.99M High: $-40.22M avg. -20.96% | Avg: $-167.44M Low: $-64.93M High: $-39.22M avg. -18.14% | Avg: $-52.75M Low: $-52.75M High: $-52.75M avg. 68.49% | Avg: $-41.26M Low: $-41.26M High: $-41.26M avg. 21.77% |
EBITDA
% change YoY
| $-141.47M N/A | $-150.60M -6.45% | $-112.59M 25.23% | Avg: $-1.53M Low: $-1.53M High: $-1.53M avg. 98.63% | Avg: $-2.46M Low: $-2.46M High: $-2.46M avg. -59.79% | Avg: $-4.02M Low: $-4.02M High: $-4.02M avg. -63.46% | Avg: $-7.54M Low: $-7.54M High: $-7.54M avg. -87.73% |
EPS
% change YoY
| -$14.85 N/A | -$15.57 -4.84% | -$11.62 25.36% | Avg: -$5.44 Low: -$8.43 High: -$3.99 avg. 53.19% | Avg: -$5.24 Low: -$6.44 High: -$3.89 avg. 3.65% | Avg: -$5.23 Low: -$5.23 High: -$5.23 avg. 0.15% | Avg: -$4.09 Low: -$4.09 High: -$4.09 avg. 21.77% |
Operating Expenses
% change YoY
| $153.62M N/A | $157.13M 2.28% | $127.59M -18.80% | Avg: $210.00M Low: $210.00M High: $210.00M avg. 64.58% | Avg: $335.57M Low: $335.57M High: $335.57M avg. 59.79% | Avg: $548.52M Low: $548.52M High: $548.52M avg. 63.46% | Avg: $1.02B Low: $1.02B High: $1.02B avg. 87.73% |
FAQ
What is Adverum Biotechnologies stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 12.79% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -84.99M, average is -141.73M and high is -40.22M.
What is Adverum Biotechnologies stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 81.20% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $7.69M, average is $7.69M and high is $7.69M.
What is Adverum Biotechnologies stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 19.69% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$8.43, average is -$5.44 and high is $-3.99.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Adverum Biotechnologies stock. The most successful analyst is Luca Issi.